Printer Friendly

Neurana Pharmaceuticals wins Notice of Allowance of Patents for Tolperisone for the large skeletal muscle relaxant market.

M2 PHARMA-May 26, 2017-Neurana Pharmaceuticals wins Notice of Allowance of Patents for Tolperisone for the large skeletal muscle relaxant market

(C)2017 M2 COMMUNICATIONS

Specialist pharmaceutical company Neurana Pharmaceuticals Inc said on Thursday that it has received a Notice of Allowance from the US Patent and Trade Office (USPTO) for two new tolperisone patents, including a second Composition of Matter patent, for a novel form of tolperisone, as well as for Method of Making patent.

According to the company, Tolperisone, which is an approved product that has regulatory approval and is commercialised in many countries outside the US, has demonstrated improvement in the treatment of skeletal muscle disorders without sedation, muscular pain, neuromuscular spasms and subsequently spasticity.

The company stated that the requirement by the US Food and Drug Administration (FDA) for a highly purified form of tolperisone provided the basis for the four patents that are either issued or subject to issuance. The tolperisone patent family term extends to 2032. Tolperisone was granted a composition of matter patent in Canada.

Under a licensing agreement, Neurana has been granted the right to develop and market Sanochemia's proprietary and patent protected tolperisone formulation in the US and other licensed territories. Neurana plans to initially develop tolperisone for the treatment of acute, painful muscle spasms as well as for spasticity.

Tolperisone has a unique, dual mechanism of action that acts on the peripheral neural system as well as in the spinal cord and brainstem to relieve severe muscular spasms and significantly improve patient mobility. The clinical studies have shown that tolperisone is efficacious without sedation, which is a common side effect of other marketed skeletal muscle relaxant products, concluded the company.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:May 26, 2017
Words:290
Previous Article:PharmaMar signs licensing agreement in Turkey with EczacA[+ or -]baAYA[+ or -] for anticancer drug Aplidin.
Next Article:Diba Industries receives US patent for multistage syringe assembly.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters